Turmoil surrounding the Greek debt crisis has brought one of our favorite stocks back down to an attractive level, so we are once again adding it our Investments Portfolio. Read More
Analyst Articles
Turmoil surrounding the Greek debt crisis has brought one of our favorite stocks back down to an attractive level, so we are once again adding it our Investments Portfolio. Read More
For the reasons described in the 6/29/2015 edition of Smart Tech 50 Weekly Movers, we are adding Meridian Biosciences (VIVO) to the Medical Profits portfolio with a buy limit price of $19 and a stop loss at $16. Read More
For the reasons described in the 6/29/2015 edition of Smart Tech 50 Weekly Movers, we are adding Meridian Biosciences (VIVO) to the Medical Profits portfolio with a buy limit price of $19 and a stop loss at $16. Read More
Is Facebook the perfect business model, or a disaster in the making? Read More
Since launching the Maximum Income for Retirees portfolio late last year we have received positive feedback from subscribers seeking greater investment income. Originally we limited each of the three sectors groups – REIT (Real Estate Investment Trust), MLP (Master Limited Partnership), and BDC (Business Development Company) – to four holdings… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
All told, over 2.5 million Americans are candidates for exoskeletons currently available or already under development. With only about 250 sold to date – and sales accelerating each month – the potential is virtually limitless. Read More